
via WHO
The drug developed by Texas A&M and University of Texas MD Anderson Cancer Center scientists could be an effective treatment for COVID-19 and other illnesses.
There’s a new drug in development that could prevent the next global pandemic. Researchers at the Texas A&M University Health Science Center (Texas A&M Health) and University of Texas MD Anderson Cancer Center are testing PUL-042, an inhaled therapeutic that provides broad protection against a range of life-threatening respiratory infections.
Results from a recent phase 2 clinical trial conducted through Houston-based biotechnology company Pulmotect, Inc. showed that it may be an effective treatment for COVID-19 and other respiratory illnesses. Patients in the trial treated with inhaled PUL-042 showed improvement in cough and shortness of breath more quickly than those who received a placebo treatment. They also experienced fewer hospitalizations and intensive care admissions.
Inhaled PUL-042 stimulates the lungs’ innate immune system, protecting against a wide variety of respiratory pathogens. The scientists behind it think PUL-042 could be directed against all existing and future variants of the COVID-19 virus, as well as future pandemics. Based on the promising results from this trial and remarkable activity in pre-clinical models, PUL-042 also has potential for use in other patient populations.
“We have not found a virus PUL-042 cannot work against in the lungs, in animal studies,” said Dr. Colin Broom, CEO of Pulmotect. “As an easily administered inhaled therapy, PUL-042 could have value in reducing the impact of COVID-19 irrespective of the development of further variants. It also has potential utility for other patient populations which we plan to explore, including immunosuppressed cancer patient.”
The innate immune system is the body’s first line of defense against invading pathogens. When germs and foreign substances enter the body, the innate immune system responds quickly to fight them off. PUL-042, the first drug in its class, is composed of two small synthetic molecules and works by stimulating specific innate immune receptors in the lung lining within minutes. Protection only lasts for about three to five days, but it can be repeatedly administered once every few days.
PUL-042 was discovered by Magnus H??k, regents and distinguished professor at the Texas A&M Health Institute of Biosciences and Technology, and Dr. Burton Dickey, chair of the pulmonary department at MD Anderson Cancer Center.
“The lungs are the point of entry for many viruses and bacteria. By activating the innate immune defense of the lungs, PUL-042 can provide effective protection against a wide range of deadly pathogens,” H??k said. “We believe that if we had this therapy available in December of 2019, we could have prevented the COVID-19 pandemic and avoided the 6 million lives lost.”
The Food and Drug Administration approved Pulmotect to begin two human clinical trials of PUL-042 last year, one focused on protection and another on treatment for COVID-19. Funding support for the trials was provided by the U.S. Department of Defense.
Original Article: New Inhaled Therapeutic Shows Promising Results Against Most Known Respiratory Infections
More from: Texas A&M University | University of Texas MD Anderson Cancer Center
The Latest on: PUL-042
- California first to cover health care for all immigrantson June 30, 2022 at 2:20 pm
California will become the first state to guarantee free health care for all low-income immigrants living in the country illegally, a move that will provide coverage for an additional 764,000 people ...
- 6 months' home confinement for ex-USC coach in college scamon June 29, 2022 at 1:45 pm
A former University of Southern California soccer coach who took bribes in exchange for helping unqualified kids into the school was sentenced Wednesday to six months in ...
- Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Insights | DelveInsighton June 29, 2022 at 9:02 am
The rising incidence of COPD and the exacerbations associated with it have been instrumental in piquing the interest of pharma players and academia in devising new therapeutic interventions for the ...
- Savaria (TSE:SIS) Has Re-Affirmed Its Dividend Of CA$0.042on June 26, 2022 at 5:39 am
The board of Savaria Corporation (TSE:SIS) has announced that it will pay a dividend of CA$0.042 per share on the 8th ... under some pressure unless EPS can pull out of the nosedive it is in.
- Savaria (TSE:SIS) Has Re-Affirmed Its Dividend Of CA$0.042on June 25, 2022 at 10:29 pm
The board of Savaria Corporation ( TSE:SIS ) has announced that it will pay a dividend of CA$0.042 per share on the ...
- A year on, Surfside remembers 98 victims of condo collapseon June 24, 2022 at 10:51 am
A year has passed since the oceanfront condo building collapse that killed 98 people in Surfside, Florida. The 12-story Champlain Towers building came down with a thunderous roar and left ...
- Spirit of Virgil Abloh lives on at Louis Vuitton in Parison June 23, 2022 at 2:51 pm
Blurring the line between fashion and performance, the Japanese house of Issey Miyake for Homme Plisse used a troupe of acrobats who contorted, danced and seemingly courted death for a ...
- Biden calls for 3-month suspension of gas and diesel taxeson June 22, 2022 at 11:35 am
President Joe Biden is calling on Congress to suspend federal gasoline and diesel taxes for three months — an election-year move meant to ease financial pressures. But it's not clear ...
- London market’s efforts at reinvigoration are flaggingon June 16, 2022 at 6:38 pm
It is probably impossible to reconcile the concerns of reformers fretting about London’s dwindling global pull and the governance guardians who value the all-in protection of the premium badge.
- Ethiopiaon November 20, 2020 at 2:07 am
There has been a lull in fighting in northern Ethiopia while the conflict continues to spread in other areas. The commission says the ongoing spread of violence in Ethiopia is "an early warning ...
via Bing News
The Latest on: PUL-042
via Google News
Add Comment